Abstract: The present invention provides a system for manufacturing a therapeutic microneedle configured to regulate an air environment within a coating chamber for manufacturing a therapeutic microneedle by coating a microneedle with a coating liquid containing a drug, the system for manufacturing a therapeutic microneedle comprising an air compressor, a humidity regulator configured to regulate humidity of air supplied from the air compressor, and an air filter configured to eliminate microorganisms from air to be supplied to the inside of the coating chamber.

Abstract: A method for producing a microneedle device having a coating on the microneedles comprises a step A of drying a precursor composition containing a biologically active substance and a first solvent to obtain -a freeze-dried composition, a step B of mixing the freeze-dried composition with a second solvent to obtain a coating composition, and a step C of applying the coating composition to the microneedles and drying the same, wherein the precursor composition further contains a thickener, or a thickener is added when the freeze-dried composition and the second solvent are mixed.

Abstract: A method for producing a microneedle device having a coating on the microneedles comprises a step A of drying a precursor composition containing a biologically active substance and a first solvent to obtain -a freeze-dried composition, a step B of mixing the freeze-dried composition with a second solvent to obtain a coating composition, and a step C of applying the coating composition to the microneedles and drying the same, wherein the precursor composition further contains a thickener, or a thickener is added when the freeze-dried composition and the second solvent are mixed.

Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains an adhesive base and an antioxidant containing a sulfur atom in its molecule.

Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains an adhesive base and an antioxidant containing a sulfur atom in its molecule.

Abstract: A method for producing a microneedle device having a coating on the microneedles comprises a step A of drying a precursor composition containing a biologically active substance and a first solvent to obtain -a freeze-dried composition, a step B of mixing the freeze-dried composition with a second solvent to obtain a coating composition, and a step C of applying the coating composition to the microneedles and drying the same, wherein the precursor composition further contains a thickener, or a thickener is added when the freeze-dried composition and the second solvent are mixed.

Abstract: A microneedle sheet according to an embodiment comprises a plurality of microneedles formed on a sheet substantially along a principal surface of the sheet. The sheet is bent to raise the microneedles from the principal surface, and the raised microneedles pierce a skin.

Abstract: The present invention provides a system for manufacturing a therapeutic microneedle configured to regulate an air environment within a coating chamber for manufacturing a therapeutic microneedle by coating a microneedle with a coating liquid containing a drug, the system for manufacturing a therapeutic microneedle comprising an air compressor, a humidity regulator configured to regulate humidity of air supplied from the air compressor, and an air filter configured to eliminate microorganisms from air to be supplied to the inside of the coating chamber.

Abstract: A microneedle sheet according to an embodiment comprises a plurality of microneedles formed on a sheet substantially along a principal surface of the sheet. The sheet is bent to raise the microneedles from the principal surface, and the raised microneedles pierce a skin.

Abstract: The present invention provides a method of coating microneedles by which the microneedles mounted on a microneedle device are coated accurately and easily in a mass-producible manner. In this method, a microneedle device (22) with a plurality of microneedles (21) is mounted on a table (23), while a mask plate (25) with a plurality of apertures (24) is fixed to a frame member (26), and a coating solution (27) is drawn in the direction of arrow A on the mask plate (25) using a spatula (28) to fill the apertures (24) with the coating solution. The microneedles (21) are inserted in the apertures (24) before or after the filling of the apertures (24) with the coating solution (27) to coat the microneedles (21).

Abstract: A GLP-1 analogue composition for a microneedle device, including a GLP-1 analogue and at least one kind of solvent selected from the group consisting of water, glycerin, propylene glycol, ethylene glycol, 1,3-butylene glycol, and polyethylene glycol.

Abstract: It is intended to provide a transdermal drug administration apparatus having microneedles, which is capable of piercing the skin by a simple procedure in the transdermal administration of a biologically active substance (drug) and allows rapid absorption of the biologically active substance. The present apparatus comprises a microneedle device (50) comprising a microneedle substrate (53) having a plurality of microneedles (51) capable of piercing the skin, an absorbent (11) disposed thereon, the absorbent (11) comprising a material capable of absorbing a liquid, and a dissolving solution reservoir (18) disposed on the absorbent (11), the dissolving solution reservoir (18) containing a dissolving solution (16) for dissolving a drug and being capable of disrupting a diaphragm (20) provided the dissolving solution reservoir (18) and the absorbent (11) by pressing. A coating containing a dry drug is disposed on the microneedles (51) and/or the microneedle substrate (53).

Abstract: An array 1 provided with microprotrusions comprises a base 2 and tapered microprotrusions 3 each disposed on the base 2 and tapering down toward the tip from the bottom. Letting a distance from the tip to the bottom on an arbitrary side of each microprotrusion 3 as a and letting the length of a second line segment prepared by projecting a first line segment representing the distance a onto the base 2 as b, a relationship of 1.0<(a/b)?7.5 holds.

Abstract: The present invention provides a micro-needle device that includes a substrate, a micro-needle provided on the substrate, and a physiologically active composition deposited on the micro-needle and/or the substrate. In the micro-needle device, the physiologically active composition contains: at least one polyhydric alcohol selected from glycerin, ethylene glycol, propylene glycol and 1,3-butylene glycol; and a physiologically active substance, and contains substantially no water.

Abstract: A microneedle device having a coating including a high molecular weight pharmaceutical compound substantially uniformly is provided. A microneedle device (1) includes a plurality of microneedles (3) on a microneedle substrate (2), which are capable of piercing the skin. A portion of or entire surface of the microneedles (3) and/or the microneedle substrate (2) has a coating including a coating carrier in a solid state. The coating carrier includes a high molecular weight pharmaceutical compound and polysaccharides compatible with the high molecular weight pharmaceutical compound. Herein, as the polysaccharide, for example, pullulan or hydroxypropylcellulose can be used.

Abstract: The present invention aims to allow high molecular weight active ingredients to be contained in a coating agent substantially uniformly. For this purpose, a microneedle device 1 includes a microneedle base 2, and microneedles 3 capable of piercing a skin and being disposed on the microneedle base 2, wherein at least a part of a surface of the microneedles 3 and/or the microneedle base 2 is coated with a coating agent containing a high molecular weight active ingredient and a water-soluble polymer, and the content of the water-soluble polymer in the coating agent is 0.1 to 30% by weight, and the ratio of the content of the water-soluble polymer to the content of the high molecular weight active ingredient in the coating agent is 5:1 to 1:100.

Abstract: Provided is a microneedle device having a microneedle base and microneedles capable of piercing the skin and being from 300 ?m to 500 ?m in height disposed on the base, where at least a part of the surface of the microneedles and/or the microneedle base is coated with a coating agent containing an active ingredient and a coating carrier, and a blending ratio of the active ingredient and the coating carrier is 10:0.1 to 1:10. Also provided are methods for administering active ingredients efficiently and simply through the skin using the microneedle device.

Abstract: The present invention provides a method of coating microneedles by which the microneedles mounted on a microneedle device are coated accurately and easily in a mass-producible manner. In this method, a microneedle device (22) with a plurality of microneedles (21) is mounted on a table (23), while a mask plate (25) with a plurality of apertures (24) is fixed to a frame member (26), and a coating solution (27) is drawn in the direction of arrow A on the mask plate (25) using a spatula (28) to fill the apertures (24) with the coating solution. The microneedles (21) are inserted in the apertures (24) before or after the filling of the apertures (24) with the coating solution (27) to coat the microneedles (21).

Abstract: A microneedle device having a coating including a high molecular weight pharmaceutical compound substantially uniformly is provided. A microneedle device (1) includes a plurality of microneedles (3) on a microneedle substrate (2), which are capable of piercing the skin. A portion of or entire surface of the microneedles (3) and/or the microneedle substrate (2) has a coating including a coating carrier in a solid state. The coating carrier includes a high molecular weight pharmaceutical compound and polysaccharides compatible with the high molecular weight pharmaceutical compound. Herein, as the polysaccharide, for example, pullulan or hydroxypropylcellulose can be used.